Cargando…
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
Aberrant activity of oncogenic rat sarcoma virus (RAS) protein promotes tumor growth and progression. RAS-driven cancers comprise more than 30% of all human cancers and are refractory to frontline treatment strategies. Since direct targeting of RAS has proven challenging, efforts have been centered...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703923/ https://www.ncbi.nlm.nih.gov/pubmed/34946644 http://dx.doi.org/10.3390/molecules26247561 |